Q3 EPS Estimates for AnaptysBio Lifted by Leerink Partnrs

Key Points

• Leerink Partners raised their Q3 2025 earnings per share estimate for AnaptysBio from ($0.85) to ($0.81), indicating a slight improvement in expected financial performance.
• The biotechnology company reported a Q2 earnings per share of ($1.34), surpassing the consensus estimate of ($1.50) and achieving revenues of $22.26 million against an expectation of $11.55 million.
• Analysts have varied opinions on AnaptysBio, with price targets ranging from $20.00 to $80.00 and ratings that include "buy," "overweight," "neutral," and others, reflecting mixed investor sentiment.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Leerink Partnrs boosted their Q3 2025 earnings per share estimates for AnaptysBio in a note issued to investors on Wednesday, October 8th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company will earn ($0.81) per share for the quarter, up from their previous estimate of ($0.85). The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q4 2025 earnings at $2.98 EPS, FY2025 earnings at $0.65 EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($3.43) EPS, FY2028 earnings at ($0.36) EPS and FY2029 earnings at $0.23 EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The business had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.

Several other equities research analysts have also recently issued reports on ANAB. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday. UBS Group reiterated a "neutral" rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. HC Wainwright boosted their price target on AnaptysBio from $38.00 to $59.00 and gave the company a "buy" rating in a research note on Tuesday, September 30th. Finally, Wedbush reiterated an "outperform" rating and issued a $45.00 price target on shares of AnaptysBio in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $48.75.

AnaptysBio Trading Down 0.2%

Shares of ANAB stock opened at $31.77 on Friday. The stock has a market cap of $889.46 million, a P/E ratio of -7.09 and a beta of -0.18. The stock has a 50 day simple moving average of $22.85 and a 200 day simple moving average of $22.21. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $36.54.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANAB. US Bancorp DE increased its holdings in shares of AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,377 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of AnaptysBio during the first quarter worth $113,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.